Journal article icon

Journal article

The economic value of targeting aging

Abstract:
Developments in life expectancy and the growing emphasis on biological and ‘healthy’ aging raise a number of important questions for health scientists and economists alike. Is it preferable to make lives healthier by compressing morbidity, or longer by extending life? What are the gains from targeting aging itself compared to efforts to eradicate specific diseases? Here we analyze existing data to evaluate the economic value of increases in life expectancy, improvements in health and treatments that target aging. We show that a compression of morbidity that improves health is more valuable than further increases in life expectancy, and that targeting aging offers potentially larger economic gains than eradicating individual diseases. We show that a slowdown in aging that increases life expectancy by 1 year is worth US$38 trillion, and by 10 years, US$367 trillion. Ultimately, the more progress that is made in improving how we age, the greater the value of further improvements.
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1038/s43587-021-00080-0

Authors


More by this author
Institution:
University of Oxford
Division:
SSD
Department:
Economics
Role:
Author
ORCID:
0000-0002-7769-5774


Publisher:
Springer Nature
Journal:
Nature Aging More from this journal
Volume:
1
Issue:
7
Pages:
616–623
Publication date:
2021-07-05
Acceptance date:
2021-05-19
DOI:
EISSN:
2662-8465


Language:
English
Keywords:
Pubs id:
1170787
Local pid:
pubs:1170787
Deposit date:
2021-04-07

Terms of use



Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP